Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

77
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
77
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

94
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
94
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

126
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
126
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

187
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
187
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

166
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
166
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.4K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sublytic C5b-9 triggers glomerular mesangial cell apoptosis in rat Thy-1 nephritis via Gadd45 activation mediated by Egr-1 and p300-dependent ATF3 acetylation.

Journal of molecular cell biology·2016
Same author

Improving the hydrogen selectivity of graphene oxide membranes by reducing non-selective pores with intergrown ZIF-8 crystals.

Chemical communications (Cambridge, England)·2016
Same author

The Association Between Genetic Polymorphism rs703842 in CYP27B1 and Multiple Sclerosis: A Meta-Analysis.

Medicine·2016
Same author

High-Flexibility, High-Toughness Double-Cross-Linked Chitin Hydrogels by Sequential Chemical and Physical Cross-Linkings.

Advanced materials (Deerfield Beach, Fla.)·2016
Same author

Synthesis, structure, and magnetic and catalytic properties of metal frameworks with 2,2'-dinitro-4,4'-biphenyldicarboxylate and imidazole-containing tripodal ligands.

Dalton transactions (Cambridge, England : 2003)·2016
Same author

Reactive oxygen species and hormone signaling cascades in endophytic bacterium induced essential oil accumulation in Atractylodes lancea.

Planta·2016

Related Experiment Video

Updated: Nov 22, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.4K

Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.

Dan Zhao1, Jian Zhu2, Ling Wang3

  • 1Statistical and Quantitative Science, Data Science Institute, Takeda Pharmaceutical Co. Limited, Cambridge, MA 02139, USA.

Contemporary Clinical Trials
|January 8, 2021
PubMed
Summary

This study introduces an improved Bayesian design for oncology clinical trials, enhancing maximum tolerated dose (MTD) estimation by utilizing all toxicity data. The new method accurately identifies MTD and reduces patient exposure to ineffective or harmful doses.

Keywords:
Adverse event summaryCumulative toxicityTarget toxicity intervalToxicity types and grades

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Related Experiment Videos

Last Updated: Nov 22, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Oncology Drug Development

Background:

  • Accurate maximum tolerated dose (MTD) estimation in oncology is crucial for patient safety and trial efficiency, especially with small sample sizes.
  • Current dose-finding designs often lose critical information by dichotomizing adverse events into dose-limiting toxicities (DLTs), leading to biased and variable MTD estimates.
  • Existing Bayesian Repeated Measures Designs (RMD) improve data utilization but rely on point estimates, which can be inconsistent in early-phase trials.

Purpose of the Study:

  • To develop an improved Bayesian Repeated Measures Design (RMD) for oncology dose-finding studies.
  • To enhance MTD estimation accuracy and reduce variability in dose escalation decisions.
  • To incorporate an interval-based decision rule for more robust dose selection.

Main Methods:

  • Proposed an improved RMD utilizing an interval-based decision rule to select doses with the highest posterior probability within a target toxicity interval.
  • Compared the proposed design against existing RMD, Continual Reassessment Method (CRM), and Bayesian Logistic Regression Model (BLRM) through comprehensive simulations.
  • Evaluated designs based on MTD estimation accuracy and patient allocation to therapeutic and toxic dose levels.

Main Results:

  • The proposed interval-based RMD demonstrated superior performance in accurately identifying the MTD compared to existing methods.
  • Fewer patients were assigned to sub-therapeutic or overly toxic doses with the proposed design.
  • The improved RMD effectively reduces variability in dose escalation decision-making, a common issue in small-sample phase I trials.

Conclusions:

  • The proposed interval-based Bayesian Repeated Measures Design offers a more accurate and reliable approach for MTD estimation in oncology dose-finding trials.
  • This design optimizes patient allocation, minimizing exposure to suboptimal doses.
  • The enhanced method addresses limitations of current designs by leveraging cumulative toxicity data more effectively.